
    
      This is a multicentre, randomised, controlled study designed to gain evidence of the
      advantage of the prophylactic, daily treatment with recombinant activated FVII as compared to
      the conventional on demand therapy in reducing the bleeding frequency and preserving the
      orthopaedic status in hemophilic children with inhibitors.
    
  